Press Releases

• Jan 12, 2021 Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
• Dec 28, 2020 Rezolute Announces Change of Transfer Agent
• Dec 3, 2020 FDA Clears Rezolute’s IND Application for RZ402
• Nov 19, 2020 Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
• Nov 5, 2020 Rezolute Announces Uplisting to the Nasdaq Capital Market
• Oct 9, 2020 Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
• Sep 10, 2020 Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
• Jul 27, 2020 Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
• Jun 15, 2020 Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
• Jun 10, 2020 Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher